Safety and Efficacy Study of the Effect of Etanercept in Hemodialysis Patients

• Status: Terminated
• Trial end date: 2010-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Etanercept is a novel anti-inflammatory agent currently used in patients with rheumatoid arthritis. We are examining whether Etanercept is effective in improving the nutritional status of hemodialysis patients as a consequence of its ability to decrease inflammation.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kaysen, George A., M.D., Ph.D.
• Collaborators: Amgen; Dialysis Clinic, Inc.
• Treatments: Etanercept

Criteria

Inclusion Criteria:

• Presence of end stage renal disease

Exclusion Criteria:

• History of Tuberculosis History of Recurrent Infection Recent AMI, Cancer within previous 5 years Presence of Hepatitis B, Hepatitis C, HIV, systemic lupus erythematosis, presence of transcutaneous access (external catheter)